Use of Sekiyama Sakura extract in improving skin condition and basal metabolism

Abstract

Use of Sekiyama cherry extract in improving skin condition and increasing basal metabolic rate. The use of Sekiyama cherry (Prunus Lannesiana) extract in improving skin condition and increasing basal metabolic rate of the present invention relates to use of Sekiyama cherry extract in producing a composition for improving skin condition or increasing basal metabolic rate, and the Sekiyama cherry extract is obtained by drying Sekiyama cherry and then extracting the dried Sekiyama cherry with a solvent, and the weight ratio of the solvent to the Sekiyama cherry is 20 to 40:1.

Description

[Technical field]

[0001] The present invention relates to uses of a cherry blossom extract, and in particular to the use of a cherry blossom extract in the production of a composition for improving skin conditions or basal metabolic rate. [Background technology]

[0002] Since the concept of organic and natural food emerged, biotechnology companies and food manufacturers have been actively engaged in the research and development of natural plant-based products. In order to provide scientifically verified evidence for the health benefits of plant-based products, the analysis of active ingredients in plants and the evaluation of their effectiveness have become important items in product development.

[0003] Guanshan cherry (Prunus Lannesiana) is one of only two edible cherry varieties in China, so biotechnology companies and food manufacturers are actively conducting active ingredient analysis and efficacy evaluation of Guanshan cherry, and developing related products based on that. Summary of the Invention [Problem to be solved by the invention]

[0004] An object of the present invention is to provide a use of Sakura extract in improving skin condition and basal metabolic rate. [Means for solving the problem]

[0005] In some embodiments, the extract of Sekiyama Sakura (Prunus Lannesiana) is used for preparing a composition for improving skin condition. The extract of Sekiyama Sakura is obtained by drying Sekiyama Sakura and then extracting the dried Sekiyama Sakura with a solvent, and the weight ratio of the solvent to the Sekiyama Sakura is 20-40:1.

[0006] In some embodiments, Sekiyama Sakura extract is used to increase collagen density in the skin.

[0007] In some embodiments, the Sekiyama Sakura extract is used to reduce wrinkles and / or fine lines on the skin.

[0008] In some embodiments, the Sekiyama Sakura extract is used to reduce skin redness.

[0009] In some embodiments, the Sekiyama Sakura extract is used to alleviate skin aging or oxidation.

[0010] In some embodiments, the Sakura extract is used to improve rough skin, improve the stability of skin condition, improve skin firmness, improve yellowing of the skin, improve skin luster, improve skin texture and smoothness, reduce skin sensitivity, or improve skin moisturization.

[0011] In some embodiments, the extract of Sekiyama cherry (Prunus Lannesiana) is used for the manufacture of a composition for improving basal metabolism. The extract of Sekiyama cherry is obtained by drying Sekiyama cherry and then extracting the dried Sekiyama cherry with a solvent, and the weight ratio of the solvent to the Sekiyama cherry is 20-40:1.

[0012] In some embodiments, the Sekiyama Sakura extract is used to improve mitochondrial activity.

[0013] In some embodiments, the Sekiyama Sakura extract is used to prevent and / or reduce DNA damage.

[0014] In some embodiments, Sekiyama Sakura extract is used to enhance antioxidant activity.

[0015] In some embodiments, the Sekiyama Sakura extract is used to inhibit the production of advanced glycation end products. Effect of the Invention

[0016] In summary, the use of the Sakura Sekiyama extract in any of the Examples for improving skin condition and improving basal metabolism is to use the Sakura Sekiyama extract in the manufacture of a composition for improving skin condition or improving basal metabolism, thereby providing a composition that can improve skin condition or improve basal metabolism in an individual when applied to the individual. That is, the composition has the effect of improving skin condition or improving basal metabolism. In some Examples, the composition obtained from the Sakura Sekiyama extract further has one or more effects of improving collagen density in the skin, reducing wrinkles and / or fine lines in the skin, inhibiting redness in the skin, alleviating skin aging or oxidation, improving rough skin, improving the stability of skin condition, improving skin firmness, improving yellowing of the skin, improving skin luster, improving skin texture and smoothness, reducing skin hypersensitivity, improving skin moisturizing, improving mitochondrial activity, preventing and / or reducing DNA damage, improving antioxidant activity, and inhibiting the production of advanced glycation end products. [Brief description of the drawings]

[0017] [Figure 1] 1 is a bar graph showing the results of a cell experiment on relative ROS production. [Diagram 2] 1 is a bar graph showing the results of cell experiments of relative mitochondrial activity. [Diagram 3] 1 is a bar graph showing the results of cell experiments of relative pyruvate content. [Figure 4] 1 is a bar graph showing the results of a cell experiment on the relative amount of DNA damage. [Diagram 5] 1 is a bar graph showing the results of a human study of blood advanced glycation endproduct concentrations at weeks 0 and 4. [Figure 6] 1 is a bar graph showing the results of a human study of relative skin collagen density at weeks 0 and 4. [Figure 7] 1 is a bar graph showing human study results of relative dermatoglyphic levels at weeks 0 and 4. [Figure 8] These are photographs of the skin markings of one of the 10 subjects at weeks 0 and 4. [Figure 9]1 is a bar graph showing the results of a human study of relative skin wrinkle levels at weeks 0 and 4. [Figure 10] Photographs of fine lines around the eyes of one of 10 subjects at weeks 0 and 4. [Figure 11] 1 is a bar graph showing human study results of relative skin redness levels at weeks 0 and 4. [Figure 12] These are photographs of skin redness in one of 10 subjects at weeks 0 and 4. [Figure 13] 1 is a graph showing the results of a skin condition questionnaire in a human test. [Figure 14] 1 is a graph showing the results of a survey on satisfaction with the effects of human testing. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0018] In the present specification, the unit of content "%" used when referring to the content generally refers to weight percentage.

[0019] In some embodiments, the Sekiyama cherry extract is obtained by an extraction procedure using Sekiyama cherry (Prunus Lannesiana) as raw material, where the extraction procedure mainly includes extracting Sekiyama cherry with a solvent and dissolving the active ingredients of Sekiyama cherry in the solvent.

[0020] In some embodiments, the Sekiyama cherry blossoms from which the extraction is performed are Sekiyama cherry blossoms. In some embodiments, the Sekiyama cherry blossoms from which the extraction is performed are in full bloom. In some embodiments, the Sekiyama cherry blossoms from which the extraction is performed include petals, calyx, and stamens.

[0021] In some embodiments, the Sekiyama cherry blossoms to be extracted are either whole and physically untreated flowers (i.e., the petals, calyx, and stamens are not separated and no physical pretreatment has been performed on their size) or physically pretreated and broken down into small sized forms such as fragments, granules, powder, etc. The physical pretreatment employed may include crushing, shredding, shearing, grinding, or polishing.

[0022] In some embodiments, the Sekiyama cherry blossoms used for extraction may be freshly picked, dried and / or frozen flowers. For example, the extraction procedure uses a solvent to extract the dried Sekiyama cherry blossoms.

[0023] In some embodiments, the procedure for carrying out the extraction process includes extracting Sekiyama cherry blossoms with water at 70° C. to 90° C. for 60 to 80 minutes to obtain a primary extract. For example, Sekiyama cherry blossoms are soaked in water at 85±5° C. for 60 minutes to dissolve the active ingredients in Sekiyama cherry blossoms in the water to obtain a primary extract.

[0024] In some embodiments, in the extraction process, the solvent is water, the raw material is Sekiyama cherry blossom, and the weight ratio of the solvent and the raw material when initially mixed is 20-40: 1. For example, the weight ratio of water to Sekiyama cherry blossom is 35: 1.

[0025] In some embodiments, the extraction process may further filter the primary extract to remove solids such as Sekiyama Sakura after extraction with water, and obtain a filtrate. For example, the primary extract may be filtered through a 400 mesh filter to remove solids, and the filtrate may be collected.

[0026] In some embodiments, the extraction process can further concentrate the filtrate to obtain a concentrate. In some embodiments, the filtrate can be concentrated under reduced pressure at 40°C to 55°C to obtain a concentrate. For example, the filtrate can be concentrated under reduced pressure at 60±5°C. In some embodiments, the length of time for concentration can be determined through the Degrees Brix of the concentrate, but is not limited thereto. In the previous example, the Brix of the obtained concentrate is 10±0.5°Bx. That is, the filtrate can be concentrated under reduced pressure at 60±5°C, and the filtrate after the reduced pressure concentration has a degree of 10±0.5°Bx, and the filtrate after the reduced pressure concentration at this time is the concentrate.

[0027] In some embodiments, during the extraction process, the primary extract may first be concentrated to form a concentrate after reducing the liquid volume, and then the concentrate is filtered to remove solids in the concentrate, and a filtrate is collected.

[0028] In some embodiments, the extraction process may involve only concentrating the primary extract or only filtering the primary extract.

[0029] It should be understood that according to actual needs, the primary extract, the filtrate, or the concentrated liquid obtained in the extraction process can be the Sekiyama Sakura extract.

[0030] In some embodiments, the above-mentioned Sakura extract has the ability to improve skin conditions, making it suitable for use in preparing a composition for improving skin conditions.

[0031] In some embodiments, the Sakura extract has the ability to increase collagen density in the skin, i.e., when applied to an individual, the Sakura extract can increase the collagen density in the skin of the individual, making the Sakura extract suitable for use in the manufacture of a composition for increasing collagen density in the skin.

[0032] In some embodiments, the Sakura extract has the ability to reduce wrinkles and / or fine lines on the skin, i.e., when applied to an individual, the Sakura extract can reduce wrinkles and / or fine lines on the skin of the individual. Therefore, the Sakura extract is suitable for the manufacture of a composition for reducing wrinkles and / or fine lines on the skin.

[0033] In some embodiments, the Sakura extract has the ability to reduce skin redness, i.e., when applied to an individual, the Sakura extract can reduce the redness of the individual's skin, making the Sakura extract suitable for use in the manufacture of a composition for reducing skin redness.

[0034] In some embodiments, the Sakura extract has the ability to alleviate skin aging or oxidation, i.e., when applied to an individual, the Sakura extract can alleviate skin aging or oxidation in that individual, making the Sakura extract suitable for use in the manufacture of a composition for alleviating skin aging or oxidation.

[0035] In some embodiments, the Sakura extract has the ability to improve rough skin, improve the stability of skin condition, improve skin firmness, improve yellowing of skin, improve skin gloss, improve skin texture and smoothness, reduce skin hypersensitivity, or improve skin moisturization. That is, when the Sakura extract is applied to an individual, it can improve the rough skin of the individual, improve the stability of the skin condition of the individual, improve the firmness of the skin of the individual, improve yellowing of the skin of the individual, improve skin gloss, improve skin texture and smoothness of the individual, reduce skin hypersensitivity, or improve skin moisturization of the individual. Therefore, the Sakura extract is suitable for the manufacture of a composition for improving rough skin, improving the stability of skin condition, improving skin firmness, improving yellowing of skin, improve skin gloss, improve skin texture and smoothness, reduce skin hypersensitivity, or improve skin moisturization.

[0036] In some embodiments, the above-mentioned Sakura extract has the ability to improve basal metabolism, and therefore, the Sakura extract is suitable for preparing a composition for improving basal metabolism.

[0037] In some embodiments, the Sakura extract has the ability to improve mitochondrial activity, i.e., when administered to an individual, the Sakura extract can improve the mitochondrial activity of the individual, making the Sakura extract suitable for use in the manufacture of a composition for improving mitochondrial activity.

[0038] In some embodiments, the Sakura extract has the ability to prevent and / or reduce DNA damage, i.e., when Sakura extract is administered to an individual, it can prevent and / or reduce DNA damage in the individual. Therefore, Sakura extract is suitable for preparing a composition for preventing and / or reducing DNA damage.

[0039] In some embodiments, the Sakura extract has the ability to enhance antioxidant activity, i.e., when administered to an individual, the Sakura extract can enhance the antioxidant activity of the individual, making the Sakura extract suitable for use in the manufacture of a composition for enhancing antioxidant activity.

[0040] In some embodiments, the Sakura extract has the ability to inhibit the formation of advanced glycation endproducts, i.e., when administered to an individual, the Sakura extract can inhibit the formation of advanced glycation endproducts in that individual, making the Sakura extract suitable for use in the manufacture of a composition for inhibiting the formation of advanced glycation endproducts.

[0041] In some embodiments, the individual may be a human.

[0042] In some embodiments, the daily intake of the Sakura extract of the composition is 0.2 grams to 0.7 grams. In some embodiments, the daily intake of the Sakura extract of the composition is 0.2 grams. In some other embodiments, the daily intake of the Sakura extract of the composition is 0.7 grams.

[0043] In some embodiments, the resulting composition produced may be a pharmaceutical composition, a non-medical edible composition, a cosmetic composition, or a skin care composition.

[0044] In some embodiments, when the composition is a pharmaceutical composition, the pharmaceutical composition contains an effective amount of Prunus Szechuan extract, which may be prepared into a dosage form suitable for enteral, parenteral, oral, or topical administration using techniques known to those skilled in the art.

[0045] In some embodiments, the dosage form of a drug administered enterally or orally can be, but is not limited to, a tablet, troche / lozenge, pill, capsule, dispersible powder or granule, solution, suspension, emulsion, syrup, elixir, slurry, or the like.

[0046] In some embodiments, the dosage form of a parenterally or topically administered drug may be, but is not limited to, an injection (e.g., a sterile aqueous solution or dispersion), a sterile powder, an external preparation, or the like.

[0047] In some embodiments, the method of administration of the injection may be, but is not limited to, an intraperitoneal injection, a subcutaneous injection, an intraepidermal injection, an intradermal injection, an intramuscular injection, an intravenous injection, or an intralesional injection.

[0048] In some embodiments, the pharmaceutical composition containing an effective amount of the Prunus sekishan extract may further include a pharma- ceutically acceptable carrier commonly used in the pharmaceutical manufacturing technology. In some embodiments, the pharma-ceutically acceptable carrier may be any one or more of a solvent, a buffer, an emulsifier, a suspending agent, a decomposer, a disintegrating agent, a dispersing agent, a binding agent, an excipient, a stabilizing agent, a chelating agent, a diluent, a gelling agent, a preservative, a wetting agent, a lubricant, an absorption delaying agent, a liposome, and the like. The type and amount of carrier selected is within the expertise and ordinary skill of the art. Among them, the solvent of the pharma- ceutically acceptable carrier may be water, normal saline, phosphate buffered saline (PBS) or an alcohol containing aqueous solution.

[0049] In some embodiments, a pharmaceutical composition containing an effective amount of Prunus Sekiyama extract may be formulated into an external preparation suitable for topical application to the skin using techniques known to those skilled in the art. In some embodiments, the external preparation may include, but is not limited to, an emulsion, gel, ointment, cream, patch, liniment, powder, aerosol, spray, lotion, serum, paste, foam, drop, suspension, salve, or bandage.

[0050] In some embodiments, when the pharmaceutical composition is an external preparation, the pharmaceutical composition may be prepared by mixing an effective amount of Prunus Szechuan extract with a base known to those skilled in the art.

[0051] In some embodiments, the base may be water, alcohols, glycols, hydrocarbons (such as petroleum, jelly, and white petrolatum), waxes (such as paraffin and yellow wax), preserving agents, antioxidants, surfactants, absorption enhancers, stabilizing agents, gelling agents (such as Carbopol® 974P, microcrystalline cellulose, and carboxymethylcellulose), active agents, humectants, odor absorbers, fragrances, pH adjusting agents, chelating agents, and the like. The composition may also include one or more additives selected from among additives such as oleaginous agents, emulsifiers, occlusive agents, emollients, thickeners, solubilizing agents, penetration enhancers, anti-irritants, colorants, propellants, etc. The selection and amounts of these additives are within the expertise and ordinary skill of one of ordinary skill in the art.

[0052] In some embodiments, when the composition is an edible composition for non-medical purposes, the edible composition contains a certain content of Sakura extract, wherein the edible composition may be in the form of powder, granule, solution, colloid, or paste.

[0053] In some embodiments, the edible composition containing the Sekiyama Sakura extract may be a food product or a food additive.

[0054] In some embodiments, the food products containing the Sakura extract may be beverages, fermented foods, bakery products, health foods, or dietary supplements, etc. In some embodiments, the food products containing the Sakura extract may further include an adjuvant. For example, the adjuvant may be maltodextrin, malic acid, sucralose, citric acid, fruit flavor, honey flavor, stevioside, or a combination thereof, etc. The type and amount of carriers selected are within the expertise and ordinary skill of the art.

[0055] In some embodiments, the food additive containing the Sekiyama cherry extract may be a seasoning, a sweetener, a flavoring, a pH adjuster, an emulsifier, a colorant, a stabilizer, and the like.

[0056] In some embodiments, the composition is a cosmetic composition or a skin care composition, i.e., the cosmetic composition or the skin care composition comprises an effective amount of Prunus sekiyama extract.

[0057] In some embodiments, the cosmetic or skin care composition containing the Sakura extract may be in the form of a lotion, gel, freeze mask, clay mask, milky lotion, cream, lipstick, foundation, powder, makeup remover oil, makeup remover milk, face wash, body wash, shampoo, hair conditioner, sunscreen, hand cream, nail polish, perfume, serum, or mask.

[0058] In some embodiments, the cosmetic or skin care composition containing the Sakura extract may further include a topically acceptable ingredient, such as an emulsifier, a penetration enhancer, an emollient, a solvent, an excipient, an antioxidant, or a combination thereof.

[0059] Unless otherwise specified in the following examples, experimental procedures are carried out at room temperature (25° C. to 30° C.) and atmospheric pressure (1 atm). EXAMPLES

[0060] Manufacturing of Sekiyama cherry extract A. Material: 1. The entire flower of Guanshan cherry (Prunus lannesiana) (origin: China), including petals, calyx, and stamens. 2. Ultrapure water, also known as RO water (reverse osmosis) or secondary distilled water, hereafter abbreviated to "water."

[0061] B. Manufacturing process: 1. The whole Guanshan cherry blossoms are oven-dried at 40-80℃, and then the dried whole Guanshan cherry blossoms are polished to form Guanshan cherry blossom powder. 2. After the water is heated to 85±5℃, the cherry blossom powder is added and soaked in the water at 85±5℃ for 60 minutes to form a primary extract containing solids. Here, the weight ratio of the cherry blossom powder to water added is 1:35. 3. The primary extract cooled to 65±5°C is filtered through a 400 mesh filter to remove solid matter (i.e., the Sekishan cherry powder after extraction) to obtain a filtrate. 4. Set the temperature of the concentrator (model: Rotavapor R-100; brand: BUCHI) to 60±5°C, then concentrate the filtrate under reduced pressure in the concentrator. When the filtrate reaches a Degrees Brix of 10±0.5°Bx, stop concentrating and obtain the concentrated liquid. 5. 1% malic acid is added to the concentrate, and the pH value of the concentrate is adjusted to pH 3.2±0.5, after which the Sekiyama cherry blossom extract is obtained. EXAMPLES

[0062] Antioxidant Test A. Materials and Equipment: 1. Cell line: human skin fibroblasts, purchased from BCRC (Bioresource Collection and Research Center), cell number 60153, hereinafter referred to as CCD-966SK cells. 2. Cell culture medium: Minimum essential medium (MEM) (purchased from Gibco, product number 11095080) supplemented with 10% Fetal Bovine Serum (purchased from Gibco, product number 10437-028), 1% Penicillin-Streptomycin (purchased from Gibco, product number 15140122), 1 mM sodium pyruvate (purchased from Gibco, product number 11360-070), 1.5 g / L sodium bicarbonate (purchased from Sigma, product number S5761-500G), and 0.1 mM non-essential amino acids. Among them, 0.1 mM of non-essential amino acids is prepared by adding and diluting MEM non-essential amino acid solution (100X) (purchased from Gibco, product number 11140050) into 99 times its volume of MEM. 3. Trypsin: 1OX trypsin (purchased from Gibco, product number 15400-054) is prepared by diluting with 9 times its volume of DPBS. 4. 100 mM H2O2 solution: Prepared with H2O2 (purchased from Sigma, product number 1.08600) and DPBS. 5. DCFH-DA working reagent: prepared with DCFH-DA (2',7'-dichlorodihydrofluorescein diacetate) (purchased from Sigma, product number SI-D6883-50MG) and DMSO (purchased from JT Baker, product number 9224-03). 6. Flow cytometer: purchased from BD.

[0063] B. Testing process: 1. 2 x 10 CCD-966SK cells in each well5 At a density of 1000×, seed into a 6-well plate containing 2 mL of cell culture medium in each well and culture at 37 °C for 24 h. Here, the CCD-966SK cells are divided into three test groups: blank group, control group, and experimental group. Each group is repeated three times. 2. After 24 hours of culturing and attaching CCD-966SK cells, each group is replaced with an experimental culture medium. The experimental culture medium of the blank group and the control group is a cell culture medium without sample, and the experimental culture medium of the experimental group is a cell culture medium containing 0.25% (m / v, mass / volume percent, weight / volume percentage, mass of solute in each unit volume of solvent) of the Sekiyama cherry extract obtained in Example 1. Then, each group is exposed to the agent at 37°C for 1 hour. 3. After the reaction for 1 hour, DCFH-DA reaction reagent was added to each group to a final concentration of 5 μg / mL, and each group was reacted at 37° C. for 15 minutes. 4. After 15 minutes of exposure, 100 mM H2O2 solution was added to the control group and the experimental group to make the final concentration 1 mM, and each group was exposed to the treatment at 37°C for 1 hour. 5. After the treatment, remove the experimental culture medium from each group and rinse twice with DPBS. 6. After rinsing, add 200μL of trypsin to each well and react for 5 minutes away from light. After the reaction, add cell culture medium to stop the reaction. Then, collect the suspended cells and cell culture medium in each well into the corresponding centrifuge tube, and centrifuge each centrifuge tube to precipitate the cells. 7. Remove the supernatant from each group of centrifuge tubes, wash the precipitated cells once with DPBS, and then add 1 mL of DPBS to each group of centrifuge tubes to resuspend the cells to form a cell suspension. 8. Set the excitation light parameters of the flow cytometer to 450-490 nm and the scattered light parameters to 510-550 nm, then use the flow cytometer to measure the green fluorescent signals of each group.

[0064] C. Test Results: The relative ROS (reactive oxygen species) production of all groups was calculated based on the following formula: relative ROS production (%) = (green fluorescent signal of each group / green fluorescent signal of blank group) x 100%.

[0065] Statistical differences between the test results of the blank group and each of the other groups and the control group and each of the other groups were obtained by Student's t-test statistical analysis. In the figure, "#" represents a p value of less than 0.05 compared to the blank group, "##" represents a p value of less than 0.01 compared to the blank group, and "###" represents a p value of less than 0.001 compared to the blank group. In addition, "*" represents a p value of less than 0.05 compared to the control group, "**" represents a p value of less than 0.01 compared to the control group, and "***" represents a p value of less than 0.001 compared to the control group.

[0066] Please refer to Figure 1. The blank group cells were not treated with samples and were not stimulated by adding H2O2, so the test results of the blank group represent the state of cells in normal physiological metabolism. Here, if the relative ROS production of the blank group is set to 100%, the relative ROS production of the control group was 348%, and the relative ROS production of the experimental group was 72%. In other words, compared with the blank group, the relative ROS production of the control group cells after stimulation by adding H2O2 significantly increased by about 248%. Compared with the control group, the relative ROS production of the experimental group cells after adding Sekiyama Sakura extract and then stimulating by adding H2O2 significantly decreased by about 79.3%. Also, compared with the blank group, the relative ROS production of the experimental group decreased by about 28%.

[0067] This shows that the Sekiyama cherry extract can significantly reduce the amount of ROS produced by skin cells due to H2O2. H2O2 induces the aerobic metabolism of cells, which produces ROS. The ROS in cells attacks macromolecules such as proteins, nucleic acids, and lipids, causing cell damage and inducing apoptosis. In other words, as the experiment proves, the Sekiyama cherry extract has the effect of enhancing the antioxidant ability of skin cells, and can alleviate cell aging caused by oxidative stress, thereby alleviating skin aging or oxidation and improving skin condition. The Sekiyama cherry extract has the effect of improving antioxidant activity. EXAMPLES

[0068] Mitochondrial activity test A. Materials and Equipment: 1. Cell line: human dermal fibroblasts, purchased from BCRC, cell number 60153, hereafter abbreviated as CCD-966SK cells. 2. Cell culture medium: MEM (Minimum essential medium) (purchased from Gibco, product number 11095080) supplemented with 10% Fetal Bovine Serum (purchased from Gibco, product number 10437-028), 1% Penicillin-Streptomycin (purchased from Gibco, product number 15140122), 1 mM sodium pyruvate (purchased from Gibco, product number 11360-070), 1.5 g / L sodium bicarbonate (purchased from Sigma, product number S5761-500G), and 0.1 mM non-essential amino acids. Among them, 0.1 mM of non-essential amino acids is prepared by adding and diluting MEM non-essential amino acid solution (100X) (purchased from Gibco, product number 11140050) into 99 times its volume of MEM. 3. Trypsin: 1OX trypsin (purchased from Gibco, product number 15400-054) is prepared by diluting with 9 times its volume of DPBS. 4. Assay buffer: This is prepared by diluting 10X Assay buffer (a reagent in the MitoScreen Flow Cytometry Mitochondrial Membrane Potential Detection Kit, purchased from BD, product number BDB551302) with 9 times its volume of DPBS, and the temperature is maintained at 37°C in a thermostatic water bath. 5. JC-1 working reagent: Dissolve JC-1 dye (a reagent in the MitoScreen Flow Cytometry Mitochondrial Membrane Potential Detection Kit, purchased from BD, product number BDB551302) in 130 μL of DMSO (purchased from JT Baker, product number 9224-03) to form a stock solution of JC-1. The stock solution of JC-1 is then diluted with 99 times its volume of Assay buffer to prepare the solution. 6. Flow cytometer: purchased from BD.

[0069] B. Testing process: 1. 1x10 CCD-966SK cells in each well 5 At a density of 1000x, seed into a 6-well plate containing 2 mL of cell culture medium in each well and culture at 37 °C for 24 h. Here, the CCD-966SK cells are divided into two test groups: a blank group and an experimental group. Each group is repeated three times. 2. After 24 hours of culturing and attaching CCD-966SK cells, each group is replaced with experimental culture medium and continuously cultured at 37°C for 24 hours. The experimental culture medium of the blank group is a cell culture medium containing no sample, and the experimental culture medium of the experimental group is a cell culture medium containing 0.25% (m / v) of the Sekiyama cherry extract obtained in Example 1. 3. After incubation, remove the experimental culture medium from each group and rinse twice with DPBS. 4. After rinsing, add 200 μL of trypsin to each well and react for 5 minutes. After the reaction, add cell culture medium to stop the reaction. Then, collect the suspended cells and cell culture medium in each well into the corresponding centrifuge tube, and centrifuge each centrifuge tube to precipitate the cells. 5. Remove the supernatant from each centrifuge tube, wash the precipitated cells twice with DPBS, and then suspend the cells again in 100 μL of JC-1 reaction reagent, mix evenly, and allow to react for 15 minutes away from light. 6. After the reaction, centrifuge each group of tubes to remove the supernatant, and wash the precipitated cells twice with assay buffer. 7. After washing, add 500 μL of DPBS to each group of centrifuge tubes to resuspend the cells to form a cell suspension. 8. Set the excitation light parameters of the flow cytometer to 488 nm, and the scattered light parameters to 527 nm and 590 nm, and then use the flow cytometer to measure the fluorescent signals of each group.

[0070] C. Test Results: The relative mitochondrial activity of every group was calculated based on the following formula: relative mitochondrial activity (%) = (fluorescence signal of each group / fluorescence signal of blank group) x 100%.

[0071] The statistical significance between the test results of the blank group and each group was obtained by the Student's t-test statistical analysis. In the figure, "*" indicates that the p value is less than 0.05 compared with the blank group, "**" indicates that the p value is less than 0.01 compared with the blank group, and "***" indicates that the p value is less than 0.001 compared with the blank group.

[0072] Please refer to Figure 2. The blank group was not treated with any sample, so the test results of the blank group represent the normal physiological metabolic state of CCD-966SK cells. Here, if the relative mitochondrial activity of the blank group is set to 100%, the relative mitochondrial activity of the experimental group is 110.07%. In other words, compared with the blank group, the relative mitochondrial activity of the CCD-966SK cells in the experimental group increased significantly by about 10.07% after the addition of the Sekiyama Sakura extract.

[0073] This shows that the Sekiyama Sakura extract can significantly improve the mitochondrial activity of skin cells. Mitochondria are the power plants of cells, providing the necessary energy to each part of the body and playing an important role in energy transmission. The higher their activity, the more vigorous the cellular physiological activity. In other words, as the experiment proves, the Sekiyama Sakura extract can increase the mitochondrial activity of cells, thereby improving cellular physiological activity, revitalizing skin cells, and promoting metabolic processes. EXAMPLES

[0074] Basal Metabolic Rate Test A. Materials and Equipment: 1. Cell line: mouse myoblast cells, purchased from ATCC (American type culture collection), cell number CRL-1772 (trademark), hereinafter abbreviated as C2C12 cells. 2. Cell culture medium: DMEM (Dulbecco's modified Eagle's medium) (purchased from Gibco, product number 12100-046) is supplemented with 10% Fetal Bovine Serum (purchased from Gibco, product number 10437-028) and 1% antibiotics, which are prepared by diluting 100X antibiotics (purchased from Gibco, product number 15240-062) into 99 times the volume of DMEM. 3. Differentiation medium: DMEM supplemented with 2% horse serum (purchased from Gibco, product number 16050-122) and 1% antibiotics. 4. Pyruvate Colorimetric / Fluorometric Assay Kit, purchased from BioVision, product number K609. 5. Enzyme immunoassay analyzer (ELISA reader): purchased from BioTek (USA).

[0075] B. Testing process: 1. 1x10 C2C12 cells in each well 6 The cells were seeded at a density of 1000×1000 cells / well into a 6-well plate containing 2 mL of cell culture medium in each well and cultured at 37° C. until 80% confluent. The test groups included a blank group and an experimental group. Each group was repeated three times. 2. After culturing until 80% confluence, replace each group with 2 mL of differentiation medium to induce differentiation of C2C12 cells into myotubes, and culture at 37°C until the cells differentiate into myotubes. 3. After the cells differentiated into myotubes, each group was replaced with 2 mL of experimental culture medium and continuously cultured at 37°C for 48 hours. The experimental culture medium of the blank group was a differentiation medium containing no sample, and the experimental culture medium of the experimental group was a differentiation medium containing 0.25% (m / v) of the Sekiyama cherry extract obtained in Example 1. 4. After culturing, remove the experimental culture medium from each group and rinse once with PBS. 5. After rinsing, the cells of each group were treated according to the test procedure provided by the pyruvate colorimetric / fluorescent assay kit to obtain the test samples of each group, and the absorbance value at 570 nm (OD ) of each test sample was measured using an enzyme immunoassay device. 570 value).

[0076] C. Test Results: The relative pyruvate content of all groups is calculated based on the following formula: Relative pyruvate content (%) = (OD of each group) 570 Value / OD of blank group 570 value) × 100%.

[0077] The statistically significant difference between the test results of the blank group and each of the other groups was obtained by the Student's t-test statistical analysis. (In the figure, "*" indicates that the p value is less than 0.05 compared with the blank group, "**" indicates that the p value is less than 0.01 compared with the blank group, and "***" indicates that the p value is less than 0.001 compared with the blank group.)

[0078] Please refer to Figure 3. The blank group was not treated with any sample, so the test results of the blank group represent the state of myotubes in normal physiological metabolism. Here, if the relative pyruvic acid content of the blank group is set to 100%, the relative pyruvic acid content of the experimental group was 142.3%. In other words, compared with the blank group, the relative pyruvic acid content of the myotubes of the experimental group increased significantly by about 42.3% after the addition of the Sekiyama Sakura extract.

[0079] This shows that the Sekishan cherry extract can significantly improve the pyruvic acid content of muscle tubules. The physiological metabolic activity of skeletal muscle cells is one of the main regulating factors of basal metabolic rate, and pyruvic acid is the end product of physiological metabolic activity, so the action status of basal metabolic rate can be evaluated through pyruvic acid content. In other words, as the experiment proves, the Sekishan cherry extract can increase the basal metabolic rate of an individual. The Sekishan cherry extract can promote the metabolism and physiological metabolism of the body, increase cell metabolism, and promote skin metabolism.

[0080] Moreover, it can be seen from Example 3 that the Guanshan cherry extract can promote mitochondrial activity, and from Example 4 that the Guanshan cherry extract can enhance cell metabolism. Therefore, the Guanshan cherry extract enhances skin activity, promotes the body's metabolism, and activates skin cells while accelerating the metabolism of waste cells, thereby achieving skin revitalization and renewal. EXAMPLES

[0081] DNA Damage Assay A. Materials and Equipment: 1. Cell line: human skin fibroblasts, purchased from ATCC, cell number CRL: 1881, hereafter abbreviated as CCD-966SK cells. 2. Cell culture medium: MEM (Minimum essential medium) (purchased from Gibco, product number 11095080) supplemented with 10% Fetal Bovine Serum (purchased from Gibco, product number 10437-028) and 1 mM sodium pyruvate (purchased from Gibco, product number 11360-070). 3. H2O2 solution: Prepared with H2O2 (purchased from Sigma, product number 1.08600) and DPBS. 4. Human Phospho-H2Ax(S139) ELISA Kit, purchased from RayBio, product number PEL-H2AX-S139-1. 5. Enzyme immunoassay analyzer (ELISA reader): purchased from BioTek (USA).

[0082] B. Testing process: 1. 2 x 10 CCD-966SK cells in each well 5 At a density of 1000×, seed into a 6-well plate containing 2 mL of cell culture medium in each well and culture at 37 °C for 24 h. Here, the CCD-966SK cells are divided into three test groups: blank group, control group, and experimental group. Each group is repeated three times. 2. After 24 hours of incubation, each group is replaced with an experimental culture medium. The experimental culture medium of the blank group and the control group is a cell culture medium without sample, and the experimental culture medium of the experimental group is a cell culture medium containing 0.125% (m / v) of the Sekiyama cherry extract obtained in Example 1. Then, each group is exposed to the treatment at 37°C for 1 hour. 3. After 1 hour of exposure, add H2O2 solution to the control group and the experimental group to a final concentration of 2 mM, and expose each group to the solution at 37℃ for 1 hour. 4. After the treatment, remove the experimental culture medium from each group and rinse it once with DPBS. 5. After rinsing, the cells of each group were treated according to the test procedure provided by the human phosphorylated histone protein H2AX (site S139) ELISA assay kit to obtain the test samples of each group, and then the absorbance value at 450 nm (OD ) of each test sample was measured using an enzyme immunoassay device. 450 value).

[0083] C. Test Results: The relative DNA damage of all groups was calculated based on the following formula: Relative DNA damage (%) = (OD of each group) 450 Value / OD of blank group 450 value) × 100%.

[0084] Statistical differences between the test results of the blank group and each of the other groups and the control group and each of the other groups were obtained by Student's t-test statistical analysis. In the figure, "#" represents a p value of less than 0.05 compared to the blank group, "##" represents a p value of less than 0.01 compared to the blank group, and "###" represents a p value of less than 0.001 compared to the blank group. In addition, "*" represents a p value of less than 0.05 compared to the control group, "**" represents a p value of less than 0.01 compared to the control group, and "***" represents a p value of less than 0.001 compared to the control group.

[0085] Please refer to Figure 4. The blank group cells were not treated with samples and were not stimulated by adding H2O2, so the test results of the blank group represent the state of cells in normal physiological metabolism. Here, if the relative DNA damage amount of the blank group is set to 100%, the relative DNA damage amount of the control group was 131.63%, and the relative DNA damage amount of the experimental group was 77.82%. In other words, compared with the blank group, the relative DNA damage amount of the control group cells increased significantly by about 31.63% after stimulation by adding H2O2. Compared with the control group, the relative DNA damage amount of the experimental group cells was significantly reduced by about 40.9% after stimulation by adding H2O2 after adding Sekiyama Sakura extract. In other words, the difference between the experimental group and the control group was 54% of the relative DNA damage amount. In addition, compared with the blank group, the relative DNA damage amount of the experimental group was reduced by about 22.2%.

[0086] This shows that the Sekiyama Sakura extract can significantly reduce the amount of DNA damage caused by H2O2 in skin cells. H2O2 induces the aerobic metabolism of cells, which produces ROS. The ROS in cells attacks macromolecules such as nucleic acids, causing DNA damage. In other words, as the experiment proves, the Sekiyama Sakura extract can significantly reduce the DNA damage caused by oxidation in skin cells, prevent and / or reduce cellular DNA damage, and promote physiological metabolism. EXAMPLES

[0087] Human Testing - Blood Testing A. Testing process: Three healthy adult subjects aged 20 years or older consumed one bottle of the test beverage (50 mL) every day for four consecutive weeks (i.e., 28 days). The test beverage contained 0.7 g of the Sekiyama cherry extract obtained in Example 1, with the remainder being water. Blood samples were also taken from the subjects before starting the test (hereinafter referred to as week 0) and after 28 days of intake (hereinafter referred to as week 4), and the amount of change in the concentration of advanced glycation end products (AGEs) in the blood before and after intake of the Sekiyama cherry extract was measured.

[0088] In this example, the measurement of the subjects' blood advanced glycation endproduct concentrations was outsourced, and the external testing agency performed blood analysis using an immunoturbidimetric assay in accordance with the blood test standards published by the Ministry of Health and Welfare of Taiwan, China.

[0089] B. Test results: Statistical significance between the test results at week 0 and week 4 was obtained by student t-test statistical analysis. In the figure, "*" represents p value less than 0.05 compared to week 0, "**" represents p value less than 0.01 compared to week 0, and "***" represents p value less than 0.001 compared to week 0.

[0090] Please refer to FIG. 5. FIG. 5 shows the change in blood advanced glycation end products concentration before and after the subjects took Sekiyama cherry extract. The blood advanced glycation end products concentration of the subjects at week 0 was about 2.6 U / mL, and at week 4 (i.e., after taking Sekiyama cherry extract for 4 consecutive weeks), the blood advanced glycation end products concentration of the subjects was significantly reduced to about 1.3 U / mL. In other words, compared to before taking the drug, after taking Sekiyama cherry extract for 4 consecutive weeks, the blood advanced glycation end products concentration of these subjects was significantly reduced by 50%. In addition, the percentage of people who were improved reached 100%. Advanced glycation end products are non-reducible substances produced after reducing sugars and proteins are bound to each other, and advanced glycation end products stimulate the production of ROS, which causes skin aging and facial dullness. This shows that Sekiyama cherry extract can reliably reduce the blood advanced glycation end products concentration. Sekiyama cherry extract can inhibit the production of advanced glycation end products and has an anti-glycation effect. In some embodiments, the Sekiyamazakura extract has the effect of preventing skin aging. EXAMPLES

[0091] Human Testing - Skin Measurements A. Testing process: Ten healthy adult subjects aged 20 years or older took one bottle of the test beverage of 50 mL every day for four consecutive weeks (i.e., 28 days). The test beverage contained 0.7 g of the Sekiyama cherry extract obtained in Example 1, and the remainder was water. In addition, the subjects were given a questionnaire survey on skin measurement and skin condition before starting to take the beverage (after washing the face, hereinafter referred to as Week 0) and after taking the beverage for 28 days (after washing the face, hereinafter referred to as Week 4). For the skin measurement, corresponding devices and measurement methods were used according to different skin measurement items, and the numerical values ​​of the facial skin were recorded, and photographs were taken before and after taking the beverage. The skin measurement items were skin collagen density, skin texture, skin wrinkles, and skin redness. In addition, whether it was Week 0 or Week 4, the temperature and humidity of the test area where the subjects were present were consistent at the time of measurement, reducing the influence of factors such as the temperature and humidity of the outside world on the skin.

[0092] Skin collagen density was measured on the facial skin of the same subject before and after 28 days of treatment using a high frequency ultrasound probe (High Freq. Ultrasound Module) purchased from Cortex Technology, Denmark (DermaLab® USB skin analysis device, Denmark). The test probe transmits sound pulse waves to the skin and converts the reflected signals of different intensities into different color scales, where the lighter or brighter the color is, the higher the collagen content of the skin is. The color scale can be calculated to obtain a numerical value representing the collagen density of the skin (hereinafter referred to as the skin collagen density value). Here, the higher the obtained skin collagen density value, the higher the skin collagen density is. The relative skin collagen density was then calculated using the following formula: relative skin collagen density (%) = (skin collagen density value of each group / skin collagen density value before treatment) x 100%.

[0093] Skin markings were measured on the facial skin of the same subject before and after 28 days of treatment using a VISIA digital skin image analysis system (VISIA Complexion Analysis System) purchased from Canfield Scientific, USA. This device photographs the facial skin with a high-resolution camera lens, measures the unevenness of the skin under standard white light irradiation, and obtains a numerical value representing the roughness of the skin's texture (hereinafter referred to as the skin marking level value) through analysis and calculation. Here, the higher the obtained skin marking level value, the coarser the skin's texture is. The relative skin marking level was then calculated using the following formula: relative skin marking level (%) = (skin marking level value of each group / skin marking level value before treatment) x 100%.

[0094] Skin wrinkles were measured on the facial skin of the same subject before and after 28 days of treatment using a VISIA digital skin image analysis system (VISIA Complexion Analysis System) purchased from Canfield Scientific, USA. This device photographs the facial skin with a high-resolution camera lens and measures the change in skin shading by irradiating it with standard white light, thereby analyzing and calculating the length and depth of wrinkles and obtaining a value representing the level of skin wrinkles (hereinafter referred to as skin wrinkle level value). Here, the higher the obtained skin wrinkle level value, the more severe the skin wrinkles. The relative skin wrinkle level was then calculated using the following formula: relative skin wrinkle level (%) = (skin wrinkle level value of each group / skin wrinkle level value before treatment) x 100%.

[0095] Skin redness was measured on the facial skin of the same subject before and after 28 days of administration using a VISIA digital skin image analysis system (VISIA Complexion Analysis System) purchased from Canfield Scientific, USA. This device uses RBX polarization technology to photograph the facial skin and measure the deep blood vessels or hemoglobin in the skin to obtain a numerical value representing the state of skin redness (hereinafter referred to as skin redness level value). Here, the higher the obtained skin redness level value, the more severe the skin redness. Then, the relative skin redness level was calculated using the following formula: relative skin redness level (%) = (skin redness level value of each group / skin redness level value before administration) × 100%.

[0096] The skin condition questionnaire survey involved subjects assessing themselves using a skin condition questionnaire, as shown in Table 1 below. Subjects self-assessed their skin condition (including overall stable skin condition, firm skin, reduced fine lines around the eyes, improved yellowing of the skin, improved skin radiance, improved skin texture and smoothness, reduced redness and sensitivity, and skin moisturization). Each subject's self-assessment of their skin condition involved selecting one of four options - strongly agree, agree, neutral, or disagree - to determine the extent to which they agreed with the skin condition.

[0097] [Table 1]

[0098] The skin condition survey also included a satisfaction questionnaire, in which subjects self-evaluated. The satisfaction with effectiveness questionnaire is shown in Table 2 below. Subjects self-evaluated their satisfaction with effectiveness. Each subject self-evaluated their overall skin condition and judged their satisfaction with the effectiveness by selecting one of four options: very satisfied, satisfied, neutral, or dissatisfied. Higher satisfaction indicates a better self-evaluation of overall skin condition.

[0099] [Table 2]

[0100] B. Test results: Statistical significance between the test results at week 0 and week 4 was obtained by student t-test statistical analysis. In the figure, "*" represents p value less than 0.05 compared to week 0, "**" represents p value less than 0.01 compared to week 0, and "***" represents p value less than 0.001 compared to week 0.

[0101] 1. Measurement results of subjects' "skin collagen density" Refer to FIG. 6. The skin collagen density obtained for the 10 subjects before taking the extract is taken as 100% relative skin collagen density. In this case, the average relative skin collagen density in the fourth week (i.e., after taking the Sekiyama cherry extract for four consecutive weeks) was 105.6%. That is, compared with before taking the extract, after taking the Sekiyama cherry extract for four consecutive weeks, the relative skin collagen density of these subjects increased by 5.6%. And the percentage of the number of people who improved reached 70%. From this, it can be seen that the Sekiyama cherry extract can reliably increase collagen, increase the skin collagen content, effectively increase collagen proliferation, provide elasticity and flexibility to the skin, and make the skin elastic, thereby improving the skin condition of the subjects and improving the skin condition. The Sekiyama cherry extract has the effect of producing skin collagen, and can increase the collagen density of the skin, giving the skin elasticity, fineness and luster.

[0102] 2. Measurement results of subjects' "skin patterns" Refer to Figure 7. The skin markings of the 10 subjects before taking the test are taken as 100% relative skin markings. In this case, the average relative skin markings level in the 4th week (i.e., after taking the Sekiyama Sakura extract for 4 consecutive weeks) was 91.1%. In other words, compared with before taking the test, after taking the Sekiyama Sakura extract for 4 consecutive weeks, the relative skin markings level of these subjects was significantly reduced by 8.9%. And the percentage of people who were improved reached 90%.

[0103] Please refer to Figure 8. Figure 8 shows the skin markings of one of the 10 subjects at week 0 and week 4. Compared with the skin markings at week 0, this subject had significantly fewer skin marks (yellow-green marks) at week 4, and the skin was significantly smoother. This shows that the Sekiyama cherry blossom extract can reliably improve skin markings, alleviate and / or improve rough skin, reduce skin irregularities, and make the skin smoother, thereby improving the skin condition of the subject and enhancing the skin condition.

[0104] 3. Measurement results regarding subjects' "skin wrinkles" Refer to Figure 9. The skin wrinkle state of 10 subjects before taking the drug is set as 100% relative skin wrinkle level. In this case, the average relative skin wrinkle level in the 4th week (i.e., after taking the Sekiyama Sakura extract for 4 consecutive weeks) was 85.7%. In other words, compared with before taking the drug, after taking the Sekiyama Sakura extract for 4 consecutive weeks, the relative skin wrinkle level of these subjects was reduced by 14.3%. And the percentage of people who were improved reached 70%.

[0105] Please refer to Figure 10. Figure 10 is a photograph of the fine lines around the eyes of one of the 10 subjects at week 0 and week 4. Compared with the fine lines around the eyes at week 0, this subject had significantly fewer and shorter fine lines around the eyes at week 4. This shows that the Sekiyama cherry extract can reliably reduce wrinkles and / or fine lines on the skin, and smooth out wrinkles and / or fine lines on the skin, thereby improving the skin condition of the subject and improving the skin condition.

[0106] 4. Measurement results regarding subjects' "skin redness" Refer to Figure 11. The skin redness state obtained for 10 subjects before taking the drug is set as 100% relative skin redness level. In this case, the average relative skin redness level in the 4th week (i.e., after taking the Sekiyama Sakura extract for 4 consecutive weeks) was 93.9%. In other words, compared with before taking the drug, after taking the Sekiyama Sakura extract for 4 consecutive weeks, the relative skin redness level of these subjects was significantly reduced by 6.1%. And the percentage of people who were improved reached 80%.

[0107] Please refer to Figure 12. Figure 12 shows photographs of the skin redness of one of the 10 subjects at week 0 and week 4. Compared to the state of skin redness at week 0, the state of skin redness of this subject at week 4 is significantly reduced. This shows that the Sekiyama cherry blossom extract can reliably suppress skin redness, reduce and / or alleviate skin redness, and thereby improve the skin condition of the subject.

[0108] 5. The results of the self-evaluation of "skin condition" are shown in FIG. 13. Ten subjects performed a self-evaluation of their skin condition at the 4th week (i.e., after taking the Sekiyama cherry extract for 4 consecutive weeks). Regarding whether their skin condition was generally stable, 10% of the subjects rated it as very likely, 70% as likely, 20% as undecided, and 0% as undecided. Regarding whether their skin was firm, 0% of the subjects rated it as very likely, 70% as likely, 30% as undecided, and 0% as undecided. Regarding whether fine lines around the eyes had decreased, 0% of the subjects rated it as very likely, 70% as likely, 30% as undecided, and 0% as undecided. Regarding whether the yellowing of the skin was improved, 20% of subjects rated it as very positive, 50% as positive, 30% as neutral, and 0% as negative. Regarding whether the skin tone was improved, 30% of subjects rated it as very positive, 50% as positive, 20% as neutral, and 0% as negative. Regarding whether the skin texture and smoothness was improved, 10% of subjects rated it as very positive, 60% as positive, 30% as neutral, and 0% as negative. Regarding whether redness and sensitivity was reduced, 10% of subjects rated it as very positive, 70% as positive, 20% as neutral, and 0% as negative. Regarding the moisturizing effect on the skin, 30% of the subjects rated it as "very agree," 50% as "agree," 20% as "neutral," and 0% as "disagree."

[0109] In other words, after taking the Sekiyama cherry extract for 4 consecutive weeks, compared to before administration, the subjects' overall skin condition can be stabilized, the skin firmness, the reduction of fine lines around the eyes, the improvement of yellowing of the skin, the improvement of skin luster, the improvement of skin texture and smoothness, the reduction of redness and hypersensitivity, and the improvement of skin moisturizing properties. In addition, 70% to 80% of the subjects reported that the above-mentioned skin condition was improved. From this, it can be seen that the Sekiyama cherry extract can definitely stabilize the overall skin condition, improve the skin firmness, reduce fine lines around the eyes, the improvement of yellowing of the skin, the improvement of skin luster, the improvement of skin texture and smoothness, the reduction of redness and hypersensitivity, and the improvement of skin moisturizing properties, and can improve the skin condition of the subjects.

[0110] 6. The results of self-evaluation of "Satisfaction with the effects" are shown in Figure 14. Ten subjects self-evaluated their satisfaction with the effects at the 4th week (i.e., after taking the Sekiyama cherry extract for 4 consecutive weeks). With regard to satisfaction with the effects, 40% of subjects answered that they were very satisfied, 40% were satisfied, 20% were undecided, and 0% were dissatisfied.

[0111] In other words, after taking the Sakura extract for 4 consecutive weeks, the overall skin condition of the subjects was improved compared to before taking the extract. Moreover, 80% of the subjects were satisfied with the effect of the Sakura extract. This shows that the Sakura extract can definitely improve the overall skin condition. [Industrial Applicability]

[0112] In summary, the use of the Sakura Sekiyama extract in any of the Examples for improving skin condition and improving basal metabolism is to use the Sakura Sekiyama extract in the manufacture of a composition for improving skin condition or improving basal metabolism, thereby providing a composition that can improve skin condition or improve basal metabolism in an individual when applied to the individual. That is, the composition has the effect of improving skin condition or improving basal metabolism. In some Examples, the composition obtained from the Sakura Sekiyama extract further has one or more effects of improving collagen density in the skin, reducing wrinkles and / or fine lines in the skin, inhibiting redness in the skin, alleviating skin aging or oxidation, improving rough skin, improving the stability of skin condition, improving skin firmness, improving yellowing of the skin, improving skin luster, improving skin texture and smoothness, reducing skin hypersensitivity, improving skin moisturizing, improving mitochondrial activity, preventing and / or reducing DNA damage, improving antioxidant activity, and inhibiting the production of advanced glycation end products.

Claims

1. A use of a Sekiyama cherry (Prunus Lannesiana) extract in the manufacture of a composition for improving skin conditions, characterized in that the Sekiyama cherry extract is obtained by drying Sekiyama cherry and then extracting the dried Sekiyama cherry with a solvent, and the weight ratio of the solvent to the Sekiyama cherry is 20 to 40:

1.

2. 2. The use of the Sakura extract according to claim 1, characterized in that the Sakura extract is used to increase collagen density in the skin.

3. 2. The use of the Sakura extract according to claim 1, characterized in that the Sakura extract is used to reduce skin wrinkles and / or fine lines.

4. 2. The use of the Sakura extract according to claim 1, wherein the Sakura extract is used to suppress redness of the skin.

5. 2. The use of the Sakura extract according to claim 1, wherein the Sakura extract is used to alleviate skin aging or oxidation.

6. 2. Use of the Sakura extract according to claim 1, characterized in that the Sakura extract is used for improving rough skin, improving the stability of skin condition, improving skin firmness, improving yellowing of the skin, improving skin luster, improving skin texture and smoothness, reducing skin hypersensitivity, or improving skin moisturizing properties.

7. A use of an extract of Sekiyama cherry tree (Prunus Lannesiana) in the manufacture of a composition for improving a basal metabolic rate, characterized in that the extract is obtained by drying Sekiyama cherry tree and then extracting the dried Sekiyama cherry tree with a solvent, and the weight ratio of the solvent to the Sekiyama cherry tree is 20 to 40:

1.

8. 8. The use of the Sekiyama-zakura extract according to claim 7, wherein the Sekiyama-zakura extract is used to improve mitochondrial activity.

9. 8. The use of the Sakura extract according to claim 7, characterized in that the Sakura extract is used to prevent and / or reduce DNA damage.

10. 8. The use of the Sekiyama-zakura extract according to claim 7, characterized in that the Sekiyama-zakura extract is used to improve antioxidant activity.

11. 8. The use of the cherry blossom extract according to claim 7, wherein the cherry blossom extract is used to inhibit the production of advanced glycation end products.

Images